1 Linking the plasma proteome to genetics in individuals from continental Africa

2 provides insights into type 2 diabetes pathogenesis

- Opeyemi Soremekun^{1,2,3}, Young-Chan Park¹, Mauro Tutino¹, Allan Kalungi³, N. William 3
- Rayner¹, Moffat Nyirenda³, Segun Fatumo^{*1,3,4}, Eleftheria Zeggini^{*1,5} 4
- 5 ¹Institute of Translational Genomics, Helmholtz Munich, 85764 Neuherberg, Germany
- 6 ²Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences,
- 7 University of KwaZulu-Natal, Westville Campus, Durban, South Africa.
- 8 ³Medical Research Council, Uganda Virus Research Institute and London School of Hygiene
- 9 and Tropical Medicine (MRC/UVRI &LSHTM), Entebbe, Uganda
- 10 ⁴Precision Healthcare University Research Institute Queen Mary University of London, United
- 11 Kingdom
- 12 ⁵TUM School of Medicine, Technical University Munich and Klinikum Rechts der Isar, 81675
- 13 Munich, Germany
- 14
- 15 *Joint Corresponding Authors
- 16
- 17

Individuals of African ancestry remain largely underrepresented in genetic and 18 19 proteomic studies. Here, we measure the levels of 2,873 proteins using the Olink 20 proximity extension assay in plasma samples from 163 individuals with type 2 diabetes 21 (T2D) or prediabetes and 362 normoglycemic controls from the Ugandan population for 22 the first time. We identify 88 differentially expressed proteins between the two groups 23 and 208 proteins associated with cardiometabolic traits. We link genome-wide data to 24 protein expression levels and construct the first protein quantitative trait locus (pOTL) 25 map in this population. We identify 399 independent associations with 346 (86.7%) cis-26 pQTLs and 53 (13.3%) trans-pQTLs. 16.7% of the cis-pQTLs and all of the trans-pQTLs 27 have not been previously reported in African-ancestry individuals. Of these, 37 pQTLs 28 have not been previously reported in any population. We find evidence for colocalization 29 between a pQTL for SIRPA and T2D genetic risk. Mendelian randomization analysis 30 identified 20 proteins causally associated with T2D. Our findings reveal proteins causally 31 implicated in the pathogenesis of T2D, which may be leveraged for personalized medicine NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 32 tailored to African-ancestry individuals.

33 Main

34 Type 2 diabetes (T2D) is becoming a major public health concern in Africa, congruent with the complex interplay of genetic, environmental and socio-economic factors ¹⁻³. The shift 35 36 from traditional to urbanized and sedentary lifestyles, accompanied by dietary changes, has contributed to this increasing prevalence⁴⁻⁶. According to the International Diabetes Federation 37 38 (IDF), it is predicted that, globally, people with T2D will rise by 51% reaching 700.2 million 39 by 2045 from 463 million in 2019⁷. A significant increase of 143% is anticipated in Africa, 40 with numbers expected to rise from 19.4 million in 2019 to 47.1 million in 2045⁷. Hemoglobin A1c (HbA1c), also known as glycated hemoglobin⁸, provides an estimate of the blood sugar 41 level over a period of two to three months by measuring the percentage of hemoglobin with 42 43 attached glucose ^{9,10}. An HbA1c level of 6.5% or higher on two separate tests typically indicates 44 diabetes. Levels between 5.7% and 6.4% suggest prediabetes, and values below 5.7% are 45 considered normal¹¹. 46

Proteins drive many biological functions, can be used as biomarkers of disease onset and progression, and are the primary targets of drug therapies. With advancement in technologies, high-throughput quantification of circulating proteins on an epidemiological scale is now possible. Combining proteomic and genomic data for blood-based pQTLs has led to the identification of hundreds of associations between genetic variants and protein levels ^{12–16}. A fraction of African-ancestry individuals in diaspora have been studied in proteomics studies to date ^{15,17}, with continental Africans largely underrepresented.

To address this, we have measured 2873 proteins using the Olink PEA Explore assay in plasma samples of 163 individuals with prediabetes or type 2 diabetes (cases) (defined as HbA1c > 5.7%) as well as 362 normoglycemic controls (defined as HbA1c < 5.7%) (Table 1). We have performed differential protein expression analysis between the two groups, and have undertaken proteomic genetic association analysis to identify sequence variants influencing protein levels. We have subsequently examined the role of the identified pQTLs in type 2 diabetes using colocalization and Mendelian randomization analysis.

- 61
- 62
- 63
- 64

All rights	reserved. No reuse	allowed without	permission.

	Cases	Controls
Number of participants (n, %)	163(31.05%)	362(68.95%)
Age (year) (mean \pm SD)	49.82 ± 18.5	50.39 ± 17.76
Male (n, %)	47(28.83%)	139(38.40%)
Female (n, %)	116(71.17%)	223(61.60%)
BMI (kg/m2)	23.4 ± 4.68	22.06 ± 4.35
HbA1c (%)	6.46 ± 1.24	5.13 ± 0.48

65 **Table 1:** Clinical Charateristics of study participants

First, we studied the association between protein levels and cardiometabolic traits measured in 66 the Ugandan cohort (supplementary 1). A total of 208 proteins were associated with HbA1c, 67 42 with HDL, and 46 with LDL at a false discovery rate (FDR) of 5% (Figure 1). Some of the 68 associations, such as ERCC1 found to be associated with HbA1c ($P_{adj} = 6.77 \times 10^{-7}$) and HDL 69 $(P_{adj} = 1.91 \times 10^{-2})$, have been shown to affect glucose intolerance in a progeroid-deficient 70 animal model causing an autoinflammatory response that leads to fat loss and insulin resistance 71 72 ¹⁸. PTPN9 was also found to be associated with HbA1c (2.96x10⁻⁶); this protein belongs to a family of protein tyrosine phosphatases (PTN) that are known to be involved in cellular insulin 73 74 resistance associated with T2D^{19,20}. Due to the role PTPN9 plays in insulin resistance, it is currently being investigated as a potential diabetes drug target ^{21,22}. 75



Figure 1: Association of protein levels with clinical traits. The y axis represents the FDRadjusted -log 10(p-value) of the association and the x axis of each plot represents the effect size

79 estimated with linear regression. [Body mass index (BMI), Systolic blood pressure (SBP), 80 Diastolic blood pressure (DBP), High density lipoproteins (HDL), Gamma glutamate transferase (GGT), Triglycerides (TG), Low density lipoproteins (LDL)]. 81

82

83 Next, we sought to identify differentially expressed protein (DEP) levels between cases and 84 controls. Using a set of 2873 unique proteins, DEPs were defined based on a 2-fold change 85 $(|\log 2FC| > 0.5)$ in expression levels at a false discovery rate (FDR) of 5%. This led to the 86 identification of 88 DEPs. Among these, 57 were found to be significantly upregulated, with 87 log2 fold changes ranging from 0.50 to 1.18, while 31 proteins were downregulated with log2 fold changes between -0.51 to -1.17 (Figure 2A), (supplementary 2). EDIL3 ((EGF-like repeats 88 89 and discoidin I-like domains 3), associated with processes such as cell adhesion, migration and vascular development, showed the most significant upregulation with an adjusted p-value of 90 1.2x10⁻¹³. EDIL3 has been shown to be differentially expressed in adipose tissue of insulin-91 92 resistant and insulin sensitive individuals ^{23,24}, and to be involved in angiogenesis ²⁵⁻²⁷. 93 Impaired angiogenesis has been implicated in the progression of diabetic retinopathy and 94 nephropathy ^{28,29}. Studies also indicate that EDIL3 is involved in inflammatory responses, which are known to contribute to insulin resistance, a hallmark of T2D³⁰. LPCAT2 95 (Lysophosphatidylcholine Acyltransferase 2) was identified as the most significantly 96 downregulated protein with Padj = 4.41×10^{-14} . LPCAT2 plays a critical role in lipid 97 metabolism, specifically in the remodeling of phospholipids in cell membranes ^{31,32}. 98 99 Downregulation of LPCAT2 may lead to changes in membrane lipids that contribute to impaired insulin signaling. The DEPs were primarily enriched in GO terms such as chemokine 100 101 receptor binding, and chemokine and cytokine activity (Figure 2B, supplementary 3). For the 102 first time, EDIL3 and LPCAT2 are identified to be differentially expressed between diabetes 103 cases and controls.





105

106 Figure 2: Volcano plot showing the differentially expressed proteins, with significantly 107 overexpressed proteins annotated in red and downregulated proteins in teal using linear model implemented in Limma (A). Gene sets significantly associated with DEPs at 5% FDR (B). 108 Biological process of significantly associated DEPs at 5% FDR(C). Cellular component of 109 significantly associated DEPs at 5% FDR using a hypergeometric test (D 110 111

112

113 We then undertook pQTL analysis with up to 15.8 million imputed variants for 2873 proteins,

114 following quality control. Using approximate conditional and joint stepwise model selection,

115 we identified 399 independent associations following multiple testing correction at P value

thresholds of $P < 1.46 \times 10^{-6}$ and $P < 2.2 \times 10^{-10}$ for cis and trans pQTLs, respectively 116

117 (supplementary 4). We identified 346 (86.7%) cis-pQTLs, and 53 (13.3%) trans-pQTLs. Seven

118 proteins had both cis- and trans-pQTLs. We also identified 4 trans-pQTLs located within the

119 following pleitropic loci: PRSS27, CDH1, EPCAM, LPO, LEG1, TSPAN8, MUC2, SELE,

IL7R, ALPI, KLK1, CDH17, CDH5, PTPRM, and SERPINI2. 120



121

Figure 3: Scatterplot of pQTL variant location against the location of the gene encoding the 122 123 target protein. Each dot represents an independent variant. Cis-pQTLs are colored in red, while 124 trans-pQTLs are colored in blue (A). 3D Manhattan plot of identified pQTLs. (x axis = proteins, 125 y axis = chromosome location, and z axis = $-\log 10$ p-values of each association) (B). Summary of identified pQTLs showing their functional consequences (C). Proportion of variance 126 127 explained (PVE) by the conditionally independent pQTLs categorized into bins (D). 128 Replication of conditionally independent pOTLs in the UKBB-PPP African-ancestry data 129 highlighting replication via p values and direction of effect (E). Assessment of the relationship 130 between the pQTLs effect sizes and minor allele frequency (MAF) (F).

131

132 To determine the novelty of the pQTLs identified in the Ugandan population, we compared 133 against pQTLs of 47 genome-wide pQTL studies (supplementary 5). We identified 6 134 independent cis-pQTLs and 31 independent trans-pQTLs that have not been previously 135 reported in any population (supplementary 6). We compared our pQTL findings against the 136 African-ancestry data of the UKBB-PPP and found that 16.7% (58 out of 346) of the 137 discorvered cis-pOTLs and all trans-pOTLs have not been previously reported (supplementary 138 7). We tested the conditionally independent Uganda population pQTLs for replication in the 139 UKBB-PPP. Of the 399 pQTLs, we were able to test 392 in the UKBB-PPP data. Of these, 303 replicated at P $\leq 1.2 \times 10^{-4}$ (Bonferroni-corrected threshold) and 270 of these also had the same 140

- 141 effect estimate direction (supplementary 8).
- 142

143 Next, we performed colocalization analysis to determine shared risk variants between the

144 pQTLs and T2D using the largest multi-ancestry genome wide association study (GWAS)

145 meta-analysis to date ³³. We found evidence for a shared T2D risk variant (posterior probability

146 4 (PP4) = 95.5%) with pQTLs for the signal regulatory protein alpha (SIRPA) protein (Figure 147 4A,B). Integrating pQTLs with T2D GWAS revealed protein-disease colocalization that may 148 suggest the involvement of SIRPA in the pathogenesis of T2D. SIRPA is a member of the SIRP 149 family and is expressed on the surface of most T cells and some B cells. Genetic studies have 150 implicated SIRP signaling in diabetes pathogenesis. For example, a SNP in human SIRPy, 151 encoding a SIRP family receptor that also binds CD47, was found to be associated with type 1 152 diabetes (T1D) ³⁴. Wong *et al.*, also identified SIRPA as a causal gene that mediates diabetes 153 susceptibility in a nonobese diabetic mouse model ³⁵.

154

160

To examine the causal relationship between the identified cis-pQTLs and T2D, we undertook 155

156 a Mendelian randomization analysis. We found 20 proteins to be causally associated with T2D.

157 Higher levels of SPINT3, SPINK6, PNLIPRP1, NAAA, HSPB1, GGACT, ENPP7, CLEC5A, and CHIT1 were associated with increased risk of T2D, while SPINK4, SHMT1, S100P, 158

159 MAPKAPK2, ECHS1, CPM, CNTN2, CNDP1, CLPS, CA5A, and ADH1B showed a protective effect on T2D risk (Figure 4C, supplementary 9). Several of these proteins such as

161 PNLIPRP1, NAAA, HSPB1, ENPP7, CLEC5A, CHIT1, SHMT1, S100P, MAPKAPK2,

162 ECHS1, CPM, CNDP1, CLPS, CA5A, and ADH1B have been shown to be associated with

163 diabetes through pathways involving lipid metabolism, inflammation, protease activity, and

hypermethlation etc ^{36–39}. PheWAS analysis also showed that some of these proteins, such as 164

165 SPINT3, SHMT1, ADH1B, and CNTN2, are associated with metabolic traits (Figure 5).

166

167 Lastly, we assembled a list of 1804 postulated effector genes for T2D from 9 GWAS studies. If a gene coding for any of the proteins associated with identified pQTL in our study was found 168 169 in the curated list, we defined such gene/protein as reported, if not, we classified them as 170 previously unresolved. We identified 320 proteins previously unresolved as potentially linked 171 to effector genes for T2D based on these GWAS signals (supplementary 10).



172

Figure 4: LocusZoom plots of the colocalizing SIRPA pQTL and T2D risk variant. The top 173 174 panel shows the T2D GWAS p-values, while the bottom panel shows pQTL p-values for the same region (A,B). Mendelian randomization forest plot for proteins causally associated with 175 176 T2D (C).



178 Figure 5: PheWAS plots for SPINT3 (A), CNTN2 (B), SHMT1 (3), and ADH1B (D).

179 Our work takes a first step toward addressing the underrepresentation of continental African 180 individuals in genetics and proteomics studies. As a result, we were able to delineate the 181 molecular landscape of 2873 unique proteins in a context that might be pivotal to understanding 182 drivers of T2D pathophysiology, identified 58 African ancestry-specific cis-pQTLs that have 183 not been reported previously, and identified 20 proteins that are causally associated with T2D. 184 The generalizability of these findings may be limited for the continent, since the population is 185 drawn from a single demographic group within Africa. There is, hence, a need to include more 186 ancestrally diverse populations in future studies.

187

188 Here, we have used the Olink targeted proteomic assay, which has some limitations, for 189 example only a subset of the full proteome is studied, and the affinity of aptamers may be 190 affected by missense variants. While HbA1c is a highly standardized and accurate test with 191 lower intraindividual variability compared to fasting glucose, in African ancestry individuals 192 using HbA1c as a blood sugar level indicator may not provide the full spectrum of the metabolic 193 conditions associated with T2D due to the prevalence of hemoglobinopathies such as glucose-194 6-phosphate dehydrogenase (G6PD) deficiency. In individuals with G6PD deficiency, there is 195 increased susceptibility to hemolysis, which may lead to reduced HbA1c level potentially 196 leading to missed T2D diagnosis ^{40,41}.

197

In conclusion, the novel associations and causally-associated proteins identified offer promising avenues for the development of targeted therapies and personalized treatment strategies for T2D, contributing to improved management and prevention of this global health challenge. Our findings demonstrate the utility and discovery opportunities afforded by the inclusion of African ancestry individuals in large-scale proteomic studies.

203 Methods

204 Study population

The participants were selected from the Uganda Genome Resource (UGR), which is a subset of the General Population Cohort (GPC). As previously described ^{42,43}, the GPC is a population-based cohort made up of over 22,000 people from 25 nearby communities in the remote Southwest Ugandan sub-county of Kyamulibwa sub-county, which is a part of Kalungu district. We selected 528 samples from the UGR based on their age, sex and HbA1c. Following

- 210 hemolysis of anticoagulated whole blood, the concentrations of total haemoglobin and HbA1c
- 211 were measured using turbidimetric inhibition immunoassay-quant Haemoglobin Alc Gen. ⁴².
- 212 In addition to the genotype QC described in ⁴², we used Hardy Weinberg p-value (pHWE) <
- 213 1x10⁻⁶.

214 Association with clinical characteristics

215 We used linear regression to determine the association between the protein levels and systolic

- 216 Systolic Blood Pressure (SBP), Diastolic Blood Pressure, alanine, albumin, alkaline, aspartate,
- 217 bilirubin, cholesterol, gamma-glutamyl transferase, High-Density Lipoprotein, Low-Density
- 218 Lipoprotein, triglycerides, and Hemoglobin A1c. All *p*-values were FDR corrected.

219 Differential Expressed Proteins and Functional enrichment

- We determined differential expressed proteins (DEP) between the cases and control using limma ⁴⁴, and we used Benjamini–Hochberg False Discovery Rate (FDR) for multiple testing ⁴⁵. DEP are defined as proteins with an FDR < 5% and a fold change greater than 0.5 (|log2FC|> 0.5). To better understand the functional impact of the proteins, we used enrichr tools from clusterProfiler ⁴⁶ and then used Pearson's correlation analysis to investigate the association between the expression levels of the DEPs. STRING database ⁴⁷ was used to generate proteinprotein interaction network for the upregulated and downregulated protein categories.
- 227

228 **Proteomics Quality Control**

229 Olink's proximity extension assay (PEA) technology ⁴⁸ was used to measure the plasma level 230 of 2978 proteins in 528 samples across eight Olink panels. The levels of protein expression 231 were measured logarithmically as Normalized Protein eXpression (NPX) units. We adjusted 232 all phenotypes using a linear regression for age, sex, plate number, sample collection season, 233 followed by an inverse-normal transformation of the residuals. During the quality control (QC) 234 process, we excluded one sample because the PCR plate well was empty, additional 2 samples 235 were further excluded due to missingness greater than 40%. Two samples SC1 and SC2 were 236 also excluded, these samples were initially included by O-link for internal control process. For 237 assay QC, 40 assays were excluded as they did not have Normalized Protein eXpression (NPX) 238 values. Additionally, we excluded 31 assays that had fraction of assay warning greater than 239 15%. No assay was excluded because of limit of detection (LOD). In all, 525 samples and 2873 240 assays remained after QC and were subsequently used for further analysis.

242 Single-point association

243 Covariates such as sex, age, plate, and mean protein expression per sample were regressed 244 using R's LM function. The residuals were then translated into z-scores and used 245 for association analysis. We used the single-point-analysis-pipeline version 0.0.2 (dev branch) 246 [https://github.com/hmgu-itg/single-point-analysis-pipeline/tree/dev] to perform the 247 association analysis. GCTA version 1.93.2 beta was used to conduct a mixed linear model 248 association (MLMA) analysis, genetic relationship matrix (GRM) function within the GCTA 249 software was used to estimate the genetic relationships among the individuals. We then used 250 GCTA-COJO, which is designed for approximate conditional and joint stepwise model 251 selection to identify independent associated variants at each locus.

252

253 Significance threshold

254 Cis significant threshold was determined by first multiplying the Bayes Factors (BF) by 2875, and values over 1 were capped at 1. The BF was estimated using eigenMT ⁴⁹. eigenMT 255 256 calculates Meff as the number of ranked eigenvalues from the adjusted genotype correlation 257 matrix needed to account for 99% of the detected genotype variability. Subsequently, the 258 corrected p values were adjusted for multiple testing by applying the False Discovery Rate 259 (FDR) method. Q-values were then calculated using the qvalue package, allowing for the 260 identification of a subset of significant associations based on a q-value threshold of <0.05. 261 Finally, the cis threshold for significance in pQTL analysis was determined by averaging the 262 smallest non-significant p-value and the largest significant p-value. This method resulted in a cis P-value threshold of 1.462E⁻⁰⁶. Trans threshold was calculated based on the effective 263 number of variants (N_{eff}) and number of protein traits (M_{eff}). The N_{eff} was derived by performing 264 265 LD-pruning with the following parameters indep 500 5 0.2 in Plink 1.9⁵⁰. This resulted in 266 an $N_{\rm eff}$ of 452593 unique variants. The $M_{\rm eff}$ was calculated using the $M_{\rm eff}$ function and Gao method in poolr R pckage ⁵¹. The trans *P*-value threshold is 2.227E⁻¹⁰. Variants within 1 267 268 megabase (Mb) upstream or downstream of the encoding genes are referred to as cis-pQTLs 269 while trans-pQTLs are those found beyond 1mb relative to the encoding gene. Ensembl's 270 Variant Effect Predictor (VEP) was used to determine the functional impact of the variants.

- 271
- 272

273 Comparison of pQTLs to prior published data

To determine the novelty of our pQTL, we used an in house-built database of previously identified signals of 46 genome-wide pQTL studies including the UKB-PPP¹⁵. We evaluated

276 novelty by identifying novel loci and novel variants. Novel loci were defined as those with no 277 published variants within ±1Mb of our variants. For variants at known loci, we checked their 278 rsIDs against those previously reported. Variants with no prior matches were further 279 conditioned in the context of other known variants at that locus. These were classified as novel 280 if the significance of their association p-value persisted even after adjusting for other known 281 variants.

282

283 Colocalisation analysis

We perform Bayesian-based colocalisation analysis using the Coloc.fast function (<u>https://github.com/tobyjohnson/gtx</u>) between our pQTL signals and multi-ancestry T2D GWAS summary statistics ³³ from DIAGRAM database. To assume shared genetics, we used default priors and posterior probability of (PP.H4) ≥ 0.8 ⁵².

288

289 Mendelian Randomization

We used the TwoSampleMR package ⁵³ to undertake an MR analysis between the proteins and African ancestry T2D to further determine causality and the direction of effect. Wald ratio test was conducted for proteins with a single cis-pQTL variant and IVW was used as the main analysis in instances with more than 1 variants.

294 Identification of Effector Genes

To find putative effector genes for T2D, we compiled effector genes associated with T2D GWAS. This dataset was curated from nine papers published in the Type 2 Diabetes Knowledge Portal (T2DKP), resulting in a collection of 1,804 distinct effector genes. For classification purposes, proteins that were documented in our curated list were labelled "reported." Those not found on the list were classified as "unresolved."

- 300
- 301 Ethics

The study was approved by the Uganda Virus Research Institute Research and Ethics Committee (UVRI REC #GC/127/907) and the Uganda National Council for Science and Technology (UNCST HS2527ES).

- 305
- **306 Code Availability**
- 307 Analyses were performed using publicly available software
- 308 Acknowledgement

309	We acknowledge the support of the Core Facility-Metabolomics and Proteomics at Helmholtz				
310	Munich. We thank the core facility for help with sample preparation and protein measurement.				
311	We thank all participants who contributed to the Uganda Genome Resource. UGR/GPC was				
312	suppo	rted by the UK Medical Research Council (MRC) and the UK Department for			
313	International Development (DFID) under the MRC/DFID Concordat agreement, through core				
314	fundiı	ng to the MRC/UVRI and LSHTM Uganda Research Unit. The 2023 Award Fellowship			
315	support of the Alexander Von Humboldt Stiftung Foundation to OS is acknowledged. SF was				
316	supported by the Wellcome Trust grant number 220740/Z/20/Z.				
317					
318					
319					
320	Refer	rence			
321	1.	Tremblay, J. & Hamet, P. Environmental and genetic contributions to diabetes.			
322		Metabolism 100, 153952 (2019).			
323	2.	Tekola-Ayele, F., Adeyemo, A. A. & Rotimi, C. N. Genetic Epidemiology of Type 2			
324		Diabetes and Cardiovascular Diseases in Africa. Prog. Cardiovasc. Dis. 56, 251–260			
325		(2013).			
326	3.	Motala, A. A., Mbanya, J. C., Ramaiya, K., Pirie, F. J. & Ekoru, K. Type 2 diabetes			
327		mellitus in sub-Saharan Africa: challenges and opportunities. Nat. Rev. Endocrinol. 18,			
328		219–229 (2022).			
329	4.	Issaka, A. et al. Association between urban-rural location and prevalence of type 2			
330		diabetes and impaired fasting glucose in West Africa: a cross-sectional population-			
331		based epidemiological study. BMJ Open 13, e063318 (2023).			
332	5.	Doherty, M. L., Owusu-Dabo, E., Kantanka, O. S., Brawer, R. O. & Plumb, J. D. Type			
333		2 diabetes in a rapidly urbanizing region of Ghana, West Africa: a qualitative study of			
334		dietary preferences, knowledge and practices. BMC Public Health 14, 1069 (2014).			
335	6.	Sidahmed, S., Geyer, S. & Beller, J. Socioeconomic inequalities in diabetes			
336		prevalence: the case of South Africa between 2003 and 2016. BMC Public Health 23,			
337		324 (2023).			
338	7.	Saeedi, P. et al. Global and regional diabetes prevalence estimates for 2019 and			
339		projections for 2030 and 2045: Results from the International Diabetes Federation			
340		Diabetes Atlas, 9(th) edition. Diabetes Res. Clin. Pract. 157, 107843 (2019).			
341	8.	Yazdanpanah, S. et al. Evaluation of glycated albumin (GA) and GA/HbA1c ratio for			

342		diagnosis of diabetes and glycemic control: A comprehensive review. Crit. Rev. Clin.
343		<i>Lab. Sci.</i> 54 , 219–232 (2017).
344	9.	Weykamp, C. HbA1c: a review of analytical and clinical aspects. Ann. Lab. Med. 33,
345		393–400 (2013).
346	10.	Day, A. HbA1c and diagnosis of diabetes. The test has finally come of age. Annals of
347		clinical biochemistry vol. 49 7–8 (2012).
348	11.	Cohen, M. P. & Hud, E. Measurement of plasma glycoalbumin levels with a
349		monoclonal antibody based ELISA. J. Immunol. Methods 122, 279-283 (1989).
350	12.	Png, G. et al. Identifying causal serum protein-cardiometabolic trait relationships
351		using whole genome sequencing. Hum. Mol. Genet. 32, 1266-1275 (2023).
352	13.	Dhindsa, R. S. et al. Rare variant associations with plasma protein levels in the UK
353		Biobank. Nature 622, 339–347 (2023).
354	14.	Zhao, J. H. et al. Genetics of circulating inflammatory proteins identifies drivers of
355		immune-mediated disease risk and therapeutic targets. Nat. Immunol. 24, 1540–1551
356		(2023).
357	15.	Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK
358		Biobank. Nature 622, 329–338 (2023).
359	16.	Gilly, A. et al. Genome-wide meta-analysis of 92 cardiometabolic protein serum
360		levels. Mol. Metab. 78, 101810 (2023).
361	17.	Zhang, J. et al. Plasma proteome analyses in individuals of European and African
362		ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat.
363		Genet. 54, 593-602 (2022).
364	18.	Karakasilioti, I. et al. DNA damage triggers a chronic autoinflammatory response,
365		leading to fat depletion in NER progeria. Cell Metab. 18, 403-415 (2013).
366	19.	Kennedy, B. P. & Ramachandran, C. Protein tyrosine phosphatase-1B in diabetes.
367		Biochem. Pharmacol. 60, 877–883 (2000).
368	20.	Hendriks, W. J. A. J. & Pulido, R. Protein tyrosine phosphatase variants in human
369		hereditary disorders and disease susceptibilities. Biochim. Biophys. Acta - Mol. Basis
370		Dis. 1832, 1673–1696 (2013).
371	21.	Yoon, SY., Ahn, D., Hwang, J. Y., Kang, M. J. & Chung, S. J. Linoleic acid exerts
372		antidiabetic effects by inhibiting protein tyrosine phosphatases associated with insulin
373		resistance. J. Funct. Foods 83, 104532 (2021).
374	22.	Chung, S. J. Dual Inhibition of PTPN6 and PTPN9. 1–13 (2024).
375	23.	Yu, Y. et al. Bioinformatics analysis of candidate genes and potential therapeutic

376 drugs targeting adipose tissue in obesity. Adipocyte 11, 1–10 (2022). 377 24. Elbein, S. C. et al. Global Gene Expression Profiles of Subcutaneous Adipose and 378 Muscle From Glucose-Tolerant, Insulin-Sensitive, and Insulin-Resistant Individuals 379 Matched for BMI. Diabetes 60, 1019–1029 (2011). 380 25. Tabasum, S. et al. EDIL3 as an Angiogenic Target of Immune Exclusion Following 381 Checkpoint Blockade. Cancer Immunol. Res. 11, 1493-1507 (2023). 382 26. Gasca, J. et al. EDIL3 promotes epithelial-mesenchymal transition and paclitaxel 383 resistance through its interaction with integrin $\alpha V\beta 3$ in cancer cells. *Cell Death* 384 Discov. 6, 86 (2020). 385 Shen, W. et al. EDIL3 knockdown inhibits retinal angiogenesis through the induction 27. 386 of cell cycle arrest in vitro . Mol Med Rep 16, 4054-4060 (2017). 387 Yu, C.-G. et al. Endothelial Progenitor Cells in Diabetic Microvascular Complications: 28. 388 Friends or Foes? Stem Cells Int. 2016, 1803989 (2016). 389 29. Tahergorabi, Z. & Khazaei, M. Imbalance of angiogenesis in diabetic complications: 390 the mechanisms. Int. J. Prev. Med. 3, 827-838 (2012). 391 30. Kumar, M. A. et al. Extracellular vesicles as tools and targets in therapy for diseases. 392 Signal Transduct. Target. Ther. 9, 27 (2024). 393 31. Abate, W., Alrammah, H., Kiernan, M., Tonks, A. J. & Jackson, S. K. 394 Lysophosphatidylcholine acyltransferase 2 (LPCAT2) co-localises with TLR4 and 395 regulates macrophage inflammatory gene expression in response to LPS. Sci. Rep. 10, 396 10355 (2020). 397 32. Wang, B. & Tontonoz, P. Phospholipid Remodeling in Physiology and Disease. Annu. 398 Rev. Physiol. 81, 165–188 (2019). 399 33. Suzuki, K. et al. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. 400 Nature 627, 347–357 (2024). 401 34. Barrett, J. C. et al. Genome-wide association study and meta-analysis find that over 40 402 loci affect risk of type 1 diabetes. Nat. Genet. 41, 703-707 (2009). 403 35. Wong, A. S. L. et al. Polymorphism in the Innate Immune Receptor SIRPa Controls 404 CD47 Binding and Autoimmunity in the Nonobese Diabetic Mouse. J. Immunol. 193, 405 4833-4844 (2014). Fanelli, F. et al. Profiling plasma N-Acylethanolamine levels and their ratios as a 406 36. 407 biomarker of obesity and dysmetabolism. Mol. Metab. 14, 82-94 (2018). 408 37. Rowles, J. E. et al. Are Heat Shock Proteins an Important Link between Type 2 409 Diabetes and Alzheimer Disease? Int. J. Mol. Sci. 21, (2020).

410	38.	Chen, ST. et al. CLEC5A is critical for dengue-virus-induced lethal disease. Nature
411		453 , 672–676 (2008).
412	39.	Maurin, L. et al. PNLIPRP1 hypermethylation in exocrine pancreas links type 2
413		diabetes and cholesterol metabolism. Diabetes (2024) doi:10.2337/db24-0215.
414	40.	Breeyear, J. H. et al. Adaptive selection at G6PD and disparities in diabetes
415		complications. Nat. Med. (2024) doi:10.1038/s41591-024-03089-1.
416	41.	Wheeler, E. et al. Impact of common genetic determinants of Hemoglobin A1c on type
417		2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-
418		wide meta-analysis. PLOS Med. 14, e1002383 (2017).
419	42.	Gurdasani, D. et al. Uganda Genome Resource Enables Insights into Population
420		History and Genomic Discovery in Africa. Cell 179, 984-1002.e36 (2019).
421	43.	Fatumo, S. et al. Uganda Genome Resource: A rich research database for genomic
422		studies of communicable and non-communicable diseases in Africa. Cell genomics 2,
423		None (2022).
424	44.	Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-
425		sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
426	45.	Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
427		Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B 57, 289-300 (1995).
428	46.	Yu, G., Wang, LG., Han, Y. & He, QY. clusterProfiler: an R package for comparing
429		biological themes among gene clusters. OMICS 16, 284–287 (2012).
430	47.	Szklarczyk, D. et al. The STRING database in 2023: protein-protein association
431		networks and functional enrichment analyses for any sequenced genome of interest.
432		Nucleic Acids Res. 51, D638–D646 (2023).
433	48.	Petrera, A. et al. Multiplatform Approach for Plasma Proteomics: Complementarity of
434		Olink Proximity Extension Assay Technology to Mass Spectrometry-Based Protein
435		Profiling. J. Proteome Res. 20, 751–762 (2021).
436	49.	Davis, J. R. et al. An Efficient Multiple-Testing Adjustment for eQTL Studies that
437		Accounts for Linkage Disequilibrium between Variants. Am. J. Hum. Genet. 98, 216-
438		224 (2016).
439	50.	Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and
440		richer datasets. Gigascience 4, 7 (2015).
441	51.	Cinar, O. & Viechtbauer, W. The poolr Package for Combining Independent and
442		Dependent p Values. J. Stat. Softw. 101, 1-42 (2022).
443	52.	Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic

- Association Studies Using Summary Statistics. PLOS Genet. 10, e1004383 (2014). 444
- 445 53. Hemani, G. et al. The MR-Base platform supports systematic causal inference across
- the human phenome. Elife 7, (2018). 446
- 447
- 448
- 449